Alyeska Investment Group
NBRV

Alyeska Investment Group’s Nabriva Therapeutics plc Ordinary Shares Ireland NBRV Stock Holding History

Alyeska Investment Group’s Portfolio NBRV Stock Details NBRV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-880
Closed -$765K – 555
2018
Q2 		$765K Sell
880
-2,293
-72% -$2.63M 0.01% 409
2018
Q1 		$3.99M Buy
3,173
+375
+13% +$555K 0.03% 307
2017
Q4 		$4.18M Buy
2,798
+2
+0.1% +$3.16K 0.03% 274
2017
Q3 		$5.72M Buy
+2,796
New +$6.56M 0.04% 284
2015
Q4 		– Sell
-210
Closed -$499K – 499
2015
Q3 		$499K Buy
+210
New +$557K 0.01% 426

Other funds holding NBRV

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $1.24B AUM 2.91% 1-Year Est. Return

Alyeska Investment Group's NBRV Position: Q3 2018 in Review

Alyeska Investment Group sold out of Nabriva Therapeutics plc Ordinary Shares Ireland (NBRV) in Q3 2018, closing a stake of 880 shares — an estimated $765K sold.

Alyeska Investment Group first reported a position in NBRV in Q3 2015 and held it in 5 quarters. The position peaked at $5.72M in Q3 2017. 45 funds tracked by Wall St. Rank hold NBRV as of Q3 2018.

  • Alyeska Investment Group reported no remaining Nabriva Therapeutics plc Ordinary Shares Ireland position as of Q3 2018 after selling out during the quarter.
  • Alyeska Investment Group sold 880 Nabriva Therapeutics plc Ordinary Shares Ireland shares in Q3 2018, an estimated $765K.
  • Alyeska Investment Group first reported a position in Nabriva Therapeutics plc Ordinary Shares Ireland in Q3 2015 and held it in 5 quarters.
  • Alyeska Investment Group's Nabriva Therapeutics plc Ordinary Shares Ireland position peaked at $5.72M in Q3 2017.
  • 45 funds tracked by Wall St. Rank held Nabriva Therapeutics plc Ordinary Shares Ireland as of Q3 2018.

Based on Alyeska Investment Group's 13F filing for Q3 2018, filed 14 Nov 2018.